Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NUWE
NUWE logo

NUWE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Nuwellis Inc (NUWE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.050
1 Day change
52 Week Range
45.420
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Nuwellis Inc (NUWE) is not a strong buy at this moment for a beginner investor with a long-term strategy. The technical indicators show a bearish trend with no significant upward momentum, and there is no positive trading sentiment or news catalysts to support a buy decision. Additionally, the company's financial performance, while showing some improvement in revenue and net income, is still weak overall, with a significant EPS drop. Given the lack of strong positive signals or catalysts, it is better to hold off on investing in this stock for now.

Technical Analysis

The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 38.484, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downtrend. Key support levels are at 0.989 and 0.895, while resistance levels are at 1.295 and 1.389.

Positive Catalysts

  • Revenue increased by 4.39% YoY in Q4 2025, and gross margin improved by 16.93% YoY to 68.23%.

Neutral/Negative Catalysts

  • The stock has a 70% chance of declining -4.88% in the next month based on candlestick pattern analysis. No recent news or trading activity from insiders, hedge funds, or Congress.

Financial Performance

In Q4 2025, revenue increased to $2,424,000 (up 4.39% YoY), and net income improved to -$2,421,000 (up 64.92% YoY). However, EPS dropped sharply to -1.5 (-91.81% YoY), indicating weak profitability despite improved gross margin (68.23%, up 16.93% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast NUWE stock price to rise
1 Analyst Rating
Wall Street analysts forecast NUWE stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 1.050
sliders
Low
5.5
Averages
5.5
High
5.5
Current: 1.050
sliders
Low
5.5
Averages
5.5
High
5.5
Roth Capital
Jonathan Aschoff
Buy
downgrade
$13 -> $11
AI Analysis
2025-05-13
Reason
Roth Capital
Jonathan Aschoff
Price Target
$13 -> $11
AI Analysis
2025-05-13
downgrade
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Nuwellis to $11 from $13 and keeps a Buy rating on the shares. While the company's Q1 revenue was down 18% quarter over quarter, pediatric utilization grew 38% year over year, the analyst tells investors in a research note. The firm believes that the four-fold increase in Aquadex Centers for Medicare & Medicaid Services reimbursement should support future revenue growth.

People Also Watch